The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Peripheral blood of cancer patients “physiologically” presents cells and cellular components
deriving from primary or metastatic sites, including circulating tumor cells (CTCs), circulating …

The level of copy number alteration (CNA), termed CNA burden, in the tumor genome is
associated with recurrence of primary prostate cancer. Whether CNA burden is associated …

Background Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of
cancers, but its utility in renal cell cancer (RCC) has not been established. Methods Here, a …

In recent years, the introduction of new molecular techniques in experimental and clinical
settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) …

Renal cell carcinoma (RCC) is a common urological malignancy and represents a leading
threat to healthcare. Recent years have seen a series of progresses in the early diagnosis …

The most common type of cancer originating in the kidney is renal cell carcinoma (RCC). In
both localized and advanced RCC, a number of clinical, pathologic, and molecular factors …

Abstract Purpose of Review We aim to summarize the current state of art about the possible
use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative …

Objectives To review urinary protein biomarkers as potential non‐invasive, easily
obtainable, early diagnostic tools in renal cell carcinoma (RCC). Methods A PubMed …

Introduction: Liquid biopsies have attracted considerable attention as potential diagnostic,
prognostic, predictive, and screening assays in oncology. The term liquid biopsies include …